Innate Pharma receives FDA approval to advance TELLOMAK 3 trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy IPHA?
FDA Review Completion: Innate Pharma's confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas has been approved by the FDA, allowing the TELLOMAK 3 trial to proceed without further comments.
Trial Design: The TELLOMAK 3 trial will be an open-label, randomized study focusing on patients with Sezary syndrome and Mycosis fungoides who have not responded to prior systemic therapy, with two independent cohorts comparing lacutamab to other treatments.
Primary Endpoint: The main goal of the study is to evaluate progression-free survival through blinded central review for both patient cohorts.
Future Prospects: The FDA's positive feedback on the regulatory pathway may lead to accelerated approval for lacutamab in treating Sezary syndrome once the Phase 3 trial begins in H1 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IPHA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IPHA
Wall Street analysts forecast IPHA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.400
Low
5.00
Averages
6.50
High
8.00
Current: 1.400
Low
5.00
Averages
6.50
High
8.00
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Innate Pharma to Host Q1 2026 Business Update Call
- Conference Call Announcement: Innate Pharma will hold a conference call on May 13, 2026, at 1:30 p.m. CEST to provide a business update for Q1 2026, aiming to enhance investor understanding of the company's progress.
- Executive Participation: The call will feature CEO Jonathan Dickinson and other executives, including Chief Medical Officer Sonia Quaratino, highlighting the leadership's commitment to transparency and communication, which is expected to bolster investor confidence.
- Live Webcast Link: The event will be available via a live webcast, allowing investors to join through the provided link, ensuring broad dissemination of information and reflecting the company's focus on investor relations.
- Replay Availability: A replay of the webcast will be accessible on the company’s website for 90 days post-event, facilitating information access for those unable to attend live, demonstrating the company's commitment to transparency.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the D. Boral Capital Global Conference on May 7, 2026, in New York, where its executive team will engage in one-on-one investor meetings aimed at enhancing investor interaction and increasing market visibility.
- Innovative Drug Development: The company is developing a portfolio of immunotherapies for cancer patients, including potential first-in-class or best-in-class assets like IPH4502, lacutamab, and monalizumab, focusing on areas of high unmet medical need, showcasing its innovation in the biotechnology sector.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca to advance innovation in immuno-oncology, which not only enhances its R&D capabilities but may also accelerate the market introduction of new therapies.
- Global Business Presence: Headquartered in Marseille, France, with an office in Rockville, MD, Innate Pharma's dual listing on Euronext and Nasdaq provides financial support and market recognition for its global business expansion.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the D. Boral Capital Global Conference on May 7, 2026, in New York, where members of its executive team will engage in one-on-one meetings with investors, aiming to enhance the company's visibility in the capital markets and attract potential investors.
- Innovative Drug Development: The company is developing several immunotherapies for cancer, including IPH4502, lacutamab, and monalizumab, targeting areas of high unmet medical need, which demonstrates Innate's innovative capabilities and market potential in the biotechnology sector.
- Strategic Partnerships: Innate has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, which not only enhance its R&D capabilities but also provide strong support for the market promotion of its products, further solidifying its position in the field of immuno-oncology.
- Global Business Presence: With its headquarters in Marseille, France, and an office in Rockville, MD, USA, Innate Pharma's international presence allows it to better access global markets, driving the development and commercialization of its innovative drugs.
See More
Innate Pharma Presents MATISSE Phase 2 Study Results
- Clinical Trial Progress: Innate Pharma will present interim results from the MATISSE Phase 2 study at the AACR Annual Meeting 2026, evaluating the combination of IPH5201 with durvalumab and chemotherapy in resectable non-small cell lung cancer (NSCLC), which is expected to garner significant attention.
- Efficacy Data Highlights: The pre-planned analysis of 40 patients showed a pathological complete response (pCR) rate of 35.7% and 50% for the combination of IPH5201 with durvalumab and chemotherapy, significantly outperforming the benchmark set by durvalumab alone, potentially offering new treatment options for NSCLC patients.
- Study Design and Objectives: The MATISSE study aims to assess the anti-tumor immune response of dual inhibition of CD39 and PD-L1 pathways combined with chemotherapy, particularly in patients with PD-L1 expression ≥50%, highlighting the necessity for novel treatment strategies in early-stage lung cancer.
- Future Research Directions: Innate Pharma will continue to recruit patients with PD-L1 expression ≥1% to further validate the efficacy of the interim results, indicating the company's ongoing commitment and innovative potential in lung cancer treatment.
See More
Innate Pharma to Hold 2026 Annual General Meeting
- AGM Details: Innate Pharma will hold its Annual General Meeting on May 21, 2026, at 10:30 a.m. CEST at its Marseille headquarters, with the notice published on April 13, 2026, ensuring shareholders are informed about the agenda and proposed resolutions.
- Attendance Requirements: Only shareholders who register their shares at least five trading days prior to the AGM, specifically by May 14, 2026, will be eligible to attend, safeguarding shareholder rights and participation.
- Laboratory Tour Opportunity: A guided tour of the company's laboratories will take place on the same day at 9:15 a.m., allowing shareholders to register via a link, thereby enhancing interaction and transparency between the company and its shareholders.
- Information Access Channels: Shareholders can submit written questions via email and access AGM-related documents on the company's investor section, ensuring timely and transparent communication of information.
See More
Innate Pharma Discloses Share and Voting Rights Information
- Total Shares Disclosure: As of April 9, 2026, Innate Pharma reports a total of 93,860,680 shares outstanding, including 93,847,763 ordinary shares and 5,336 preferred shares, indicating stability in its capital structure which aids investors in assessing market position.
- Voting Rights Information: The company has a total of 94,484,443 theoretical voting rights and 94,465,868 exercisable voting rights, ensuring transparency in corporate governance and compliance with French financial market regulations, which may positively influence stock price stability.
- Compliance and Transparency: Innate Pharma's disclosures align with the French Commercial Code and AMF regulations, enhancing investor trust in corporate governance and compliance, potentially leading to a more stable stock performance.
- Company Background: Innate Pharma is a global clinical-stage biotechnology firm focused on developing immunotherapies for cancer, with a portfolio of differentiated potential first and/or best-in-class assets, showcasing its innovative capabilities and market potential in the biopharmaceutical sector.
See More
Innate Pharma to Host Q1 2026 Business Update Call
- Conference Call Announcement: Innate Pharma will hold a conference call on May 13, 2026, at 1:30 p.m. CEST to provide a business update for Q1 2026, aiming to enhance investor understanding of the company's progress.
- Executive Participation: The call will feature CEO Jonathan Dickinson and other executives, including Chief Medical Officer Sonia Quaratino, highlighting the leadership's commitment to transparency and communication, which is expected to bolster investor confidence.
- Live Webcast Link: The event will be available via a live webcast, allowing investors to join through the provided link, ensuring broad dissemination of information and reflecting the company's focus on investor relations.
- Replay Availability: A replay of the webcast will be accessible on the company’s website for 90 days post-event, facilitating information access for those unable to attend live, demonstrating the company's commitment to transparency.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the D. Boral Capital Global Conference on May 7, 2026, in New York, where its executive team will engage in one-on-one investor meetings aimed at enhancing investor interaction and increasing market visibility.
- Innovative Drug Development: The company is developing a portfolio of immunotherapies for cancer patients, including potential first-in-class or best-in-class assets like IPH4502, lacutamab, and monalizumab, focusing on areas of high unmet medical need, showcasing its innovation in the biotechnology sector.
- Strategic Partnerships: Innate Pharma has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca to advance innovation in immuno-oncology, which not only enhances its R&D capabilities but may also accelerate the market introduction of new therapies.
- Global Business Presence: Headquartered in Marseille, France, with an office in Rockville, MD, Innate Pharma's dual listing on Euronext and Nasdaq provides financial support and market recognition for its global business expansion.
See More
Innate Pharma to Participate in Investor Meetings
- Investor Meeting Schedule: Innate Pharma will participate in the D. Boral Capital Global Conference on May 7, 2026, in New York, where members of its executive team will engage in one-on-one meetings with investors, aiming to enhance the company's visibility in the capital markets and attract potential investors.
- Innovative Drug Development: The company is developing several immunotherapies for cancer, including IPH4502, lacutamab, and monalizumab, targeting areas of high unmet medical need, which demonstrates Innate's innovative capabilities and market potential in the biotechnology sector.
- Strategic Partnerships: Innate has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, which not only enhance its R&D capabilities but also provide strong support for the market promotion of its products, further solidifying its position in the field of immuno-oncology.
- Global Business Presence: With its headquarters in Marseille, France, and an office in Rockville, MD, USA, Innate Pharma's international presence allows it to better access global markets, driving the development and commercialization of its innovative drugs.
See More
Innate Pharma Presents MATISSE Phase 2 Study Results
- Clinical Trial Progress: Innate Pharma will present interim results from the MATISSE Phase 2 study at the AACR Annual Meeting 2026, evaluating the combination of IPH5201 with durvalumab and chemotherapy in resectable non-small cell lung cancer (NSCLC), which is expected to garner significant attention.
- Efficacy Data Highlights: The pre-planned analysis of 40 patients showed a pathological complete response (pCR) rate of 35.7% and 50% for the combination of IPH5201 with durvalumab and chemotherapy, significantly outperforming the benchmark set by durvalumab alone, potentially offering new treatment options for NSCLC patients.
- Study Design and Objectives: The MATISSE study aims to assess the anti-tumor immune response of dual inhibition of CD39 and PD-L1 pathways combined with chemotherapy, particularly in patients with PD-L1 expression ≥50%, highlighting the necessity for novel treatment strategies in early-stage lung cancer.
- Future Research Directions: Innate Pharma will continue to recruit patients with PD-L1 expression ≥1% to further validate the efficacy of the interim results, indicating the company's ongoing commitment and innovative potential in lung cancer treatment.
See More
Innate Pharma to Hold 2026 Annual General Meeting
- AGM Details: Innate Pharma will hold its Annual General Meeting on May 21, 2026, at 10:30 a.m. CEST at its Marseille headquarters, with the notice published on April 13, 2026, ensuring shareholders are informed about the agenda and proposed resolutions.
- Attendance Requirements: Only shareholders who register their shares at least five trading days prior to the AGM, specifically by May 14, 2026, will be eligible to attend, safeguarding shareholder rights and participation.
- Laboratory Tour Opportunity: A guided tour of the company's laboratories will take place on the same day at 9:15 a.m., allowing shareholders to register via a link, thereby enhancing interaction and transparency between the company and its shareholders.
- Information Access Channels: Shareholders can submit written questions via email and access AGM-related documents on the company's investor section, ensuring timely and transparent communication of information.
See More
Innate Pharma Discloses Share and Voting Rights Information
- Total Shares Disclosure: As of April 9, 2026, Innate Pharma reports a total of 93,860,680 shares outstanding, including 93,847,763 ordinary shares and 5,336 preferred shares, indicating stability in its capital structure which aids investors in assessing market position.
- Voting Rights Information: The company has a total of 94,484,443 theoretical voting rights and 94,465,868 exercisable voting rights, ensuring transparency in corporate governance and compliance with French financial market regulations, which may positively influence stock price stability.
- Compliance and Transparency: Innate Pharma's disclosures align with the French Commercial Code and AMF regulations, enhancing investor trust in corporate governance and compliance, potentially leading to a more stable stock performance.
- Company Background: Innate Pharma is a global clinical-stage biotechnology firm focused on developing immunotherapies for cancer, with a portfolio of differentiated potential first and/or best-in-class assets, showcasing its innovative capabilities and market potential in the biopharmaceutical sector.
See More
